Substitute for	form 1449A/F	то		Complete if Known		
INICOD	8.6.A TIO.	LDICO	COURT	Application Number	10/509,055	
			LOSURE	Filing Date	09-24-04	
STATE	MENT I	BY APF	PLICANT	First Named Inventor	Hiroaki Sagawa	
				Art Unit	1644	
(Us	se as many sh	eets as nece	essary)	Examiner Name	A. JUEDES	
Sheet	1	of	7	Attorney Docket Number	1422-0644PUS1	

			U.S. F	PATENT DOCUMENTS	
Examiner initial *	Cite No. <sup>1</sup>	Document Number  Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-2004/115809 - A1	06-17-2004	Sagawa et al.	
	2	US-2005/227354 - A1	10-13-2005	Sagawa et al.	
	3	US-2006/166924 - A1	07-27-2006	Kato et al.	
	4	US-2006/246587 - A1	11-02-2006	June et al.	
	5	US-2008/227204 - A1	09-18-2008	Sagawa et al.	
	6	US-5,102,988 - A	04-07-1992	Kimizuka et al.	
	7	US-5,198,423 - A	03-30-1993	Taguchi et al.	
	8	US-5,354,686 - A	10-14-1994	Haberman	
	9	US-5,827,642 - A	10-27-1998	Riddell et al.	
	10	US-5,866,115 - A	02-02-1999	Kanz et al.	
	11	US-6,316,257 - B1	11-13-2001	Flyer et al.	
	12	US-6,692,964 - B1	02-17-2004	June et al.	
	13	US-6,734,014 - B1	05-11-2004	Hwu et al.	
	14	US-6,821,778 - B1	11-23-2004	Engleman et al.	
·	15	US-7,067,318 - B2	06-27-2006	June et al.	
	16	US-7,172,869 - B2	02-06-2007	June et al.	

			FO	REIGN PATENT [	OCUMENTS		
Examiner Initial *	Cite No. 1		Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited	Pages, columns, Lines, Where Relevant	
		Country Code	Number Kind Code (if known) 5	MM-DD-YYYY	Document	Passages or Relevant Figures Appear	Т6
	17	wo	00/56368 - A1	09-28-2000			
	18	wo	02/14481 - A1	02-21-2002			
	19	wo	03/080817 - A1	10-02-2003			௱
	20	EP	0523948 - A2	01-20-1993			
	21	EP	0795606 - A1	09-17-1997			1
	22	EP	1496109 - A1	01-12-2005			1
	23	JP	2003-80817 - A	03-19-2003			厅
	24	wo	88/02774 - A1	04-21-1988			
	25	JP	9-25299 - A	01-28-1997			忊一
	26	wo	95/28479 - A1	10-26-1995			$\dagger \Box \dagger$

Examiner Signature	Date Considered	
	 1	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not Considered. Include of this form with next communication to applicant.

<sup>1.</sup> Applicant's unique citation designation number (optional) 2. See Kinds codes of USPTO patent Documents, at www.uspto.gov or MPEP 901.04.

<sup>3.</sup> Enter Office that isssued the document, by the two-letter code (WIPO Standard ST.3.) 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.f 16 if possible. 6. Applicant is to place a check mark here if English language Translation is attached.

Substitute for	r form 1449A/PT	го		Complete if Known		
INICOD		DIGGL	001105	Application Number	10/509,055	
	MATION			Filing Date	09-24-04	
STATE	EMENT B	3Y APPL	_ICANT	First Named Inventor	Hiroaki Sagawa	
				Art Unit	1644	
(U	se as many she	ets as necess	sary)	Examiner Name	A. JUEDES	
Sheet	2	of	7	Attorney Docket Number	1422-0644PUS1	

	U.S. PATENT DOCUMENTS									
Examiner initial *	Cite No. 1	Document Number	Publication Date	Name of Patentee or	Pages, columns, Lines, Where					
nadar	NO.	Number - Kind Code <sup>2</sup> (if known)	MM-DD-YYYY	Applicant of Cited Document	Pages, columns, Lines, Where Relevant Passages or Relevant Figures Appear					
					Annibited substitution for the supplication of					
***************************************										
				The second secon						
		WATER CONTROL OF THE								

			FO	REIGN PATENT D	OCUMENTS		
Examiner Initial *	Cite No. 1	Foreign Patent Document  Country <sup>3</sup> Number <sup>4</sup> Kind Code (if known) <sup>5</sup> Code		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, columns, Lines, Where Relevant Passages or Relevant Figures Appear	Т6
	27	wo	97/11694 - A1	04-03-1997			Г
	28	wo	99/33863 - A1	07-08-1999			T
							T
							T
							忊
					A		$\top$
			The state of the s				T
							1
							T

Examiner Signature	Date Considered	

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not Considered. Include of this form with next communication to applicant.

<sup>1.</sup> Applicant's unique citation designation number (optional) 2. See Kinds codes of USPTO patent Documents, at www.uspto.gov or MPEP 901.04.

<sup>3.</sup> Enter Office that isssued the document, by the two-letter code (WIPO Standard ST.3.) 4. For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.f. 16 if possible. 6. Applicant is to place a check mark here if English language Translation is attached.

Substitut	e for form 1449B/PT	ю		Complete if Known		
INIE		פוח ו	CLOSURE	Application Number	10/509,055	
				Filing Date	09-24-04	
517	ATEMENT E	SYA	PPLICANI	First Named Inventor	Hiroaki Sagawa	
				Group Art Unit	1644	
	(Use as many she	ets as n	ecessary)	Examiner Name	A. JUEDES	
Sheet	3	of	7	Attorney Docket Number	1422-0644PUS1	

"Animal Cell Culture", Freshney, Ed. 1986, IRL Press, Oxford, Washington, DC, Sections 2.1, 3.2.2-3.2.6, 5, 6.1-6.3, 3.1-3.4  "Animal Cell Culture: A Practical Approach", Edited by R. I. Freshney, IRL Press, Oxford, Washington, DC, 1986, pp. 26-41  AZUMA et al., "Functional Expression of B7/BB1 on Activated T Lymphocytes", J. Exp. Med., Vol. 177, March 1993, pp. 845-850  BLUE et al. "Enhancement of CD2-Mediated T Cell Activation by the Interaction of VLA-4 with Fibronectin", Cellular Immunology, Vol. 138, 1991, pp. 238-244  BPAI Decision on Appeal for Application No. 10/344,534, dated May 28, 2010  del POZO et al., "Chemokines Regulate Cellular Polarization and Adhesion Receptor Redistribution During Lymphocyte Interaction with Endothelium and Extracellular Matrix, Involvement of cAMP Signaling Pathway", The Journal of Cell Biology, Vol. 131, No. 2, October 1995, pp. 495-508  Examiner Interview Summary for US Application No. 10/344,534, dated February 5, 2008			NON PATENT LITERATURE DOCUMENTS	
29 3.2.2-3.2.6, 5, 6.1-6.3, 3.1-3.4  "Animal Cell Culture: A Practical Approach", Edited by R. I. Freshney, IRL Press, Oxford, Washington, DC, 1986, pp. 26-41  AZUMA et al., "Functional Expression of B7/BB1 on Activated T Lymphocytes", J. Exp. Med., Vol. 177, March 1993, pp. 845-850  BLUE et al. "Enhancement of CD2-Mediated T Cell Activation by the Interaction of VLA-4 with Fibronectin", Cellular Immunology, Vol. 138, 1991, pp. 238-244  BPAI Decision on Appeal for Application No. 10/344,534, dated May 28, 2010  del POZO et al., "Chemokines Regulate Cellular Polarization and Adhesion Receptor Redistribution During Lymphocyte Interaction with Endothelium and Extracellular Matrix, Involvement of cAMP Signaling Pathway", The Journal of Cell Biology, Vol. 131, No. 2, October 1995, pp. 495-508  Examiner Interview Summary for US Application No. 10/344,534, dated February 5, 2008  Extended European Search Report, Application No. EP 09004189.8-1222/2070542, December 8, 2009, 6 pages  FUNARO et al., "Stimulation of T Cellis via CD44 Requires Leukoyte-Function-Associated Antigen Interactions and Interleukin-2 Production, Human Immunology, Vol. 40, No. 4, August 1994, pp. 267-278 [  JOHNSON et al., "Expression and Function of Insulin-Like Growth Factor Receptors on Anti-CD3-Activated Human T Lymphyocytes", Journal of Immunology, Vol. 148, No. 1, January 1, 1992, pp. 63-71  KANTO et at, "Neutralization of Transforming Growth Factor 8-1 Augments Hepatitis C Virus-Specific Cytotoxic T Lymphocyte Induction In Vitro", Journal of Clinical Immunology, Vol. 17, No. 6, 1997, pp.			item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	Т <sup>2</sup>
AZUMA et al., "Functional Expression of B7/BB1 on Activated T Lymphocytes", J. Exp. Med., Vol. 177, March 1993, pp. 845-850  BLUE et al. "Enhancement of CD2-Mediated T Cell Activation by the Interaction of VLA-4 with Fibronectin", Cellular Immunology, Vol. 138, 1991, pp. 238-244  BPAI Decision on Appeal for Application No. 10/344,534, dated May 28, 2010  del POZO et al., "Chemokines Regulate Cellular Polarization and Adhesion Receptor Redistribution During Lymphocyte Interaction with Endothelium and Extracellular Matrix, Involvement of cAMP Signaling Pathway", The Journal of Cell Biology, Vol. 131, No. 2, October 1995, pp. 495-508  Examiner Interview Summary for US Application No. 10/344,534, dated February 5, 2008  Extended European Search Report, Application No. EP 09004189.8-1222/2070542, December 8, 2009, 6 pages  FUNARO et al., "Stimulation of T CellIs via CD44 Requires Leukoyte-Function-Associated Antigen Interactions and Interleukin-2 Production, Human Immunology, Vol. 40, No. 4, August 1994, pp. 267-278 JOHNSON et al., "Expression and Function of Insulin-Like Growth Factor Receptors on Anti-CD3-Activated Human T Lymphyocytes", Journal of Immunology, Vol. 148, No. 1, January 1, 1992, pp. 63-71  KANTO et at, "Neutralization of Transforming Growth Factor 8-1 Augments Hepatitis C Virus-Specific Cytotoxic T Lymphocyte Induction In Vitro", Journal of Clinical Immunology, Vol. 17, No. 6, 1997, pp.		29		
BLUE et al. "Enhancement of CD2-Mediated T Cell Activation by the Interaction of VLA-4 with Fibronectin", Cellular Immunology, Vol. 138, 1991, pp. 238-244  BPAI Decision on Appeal for Application No. 10/344,534, dated May 28, 2010  del POZO et al., "Chemokines Regulate Cellular Polarization and Adhesion Receptor Redistribution During Lymphocyte Interaction with Endothelium and Extracellular Matrix, Involvement of cAMP Signaling Pathway", The Journal of Cell Biology, Vol. 131, No. 2, October 1995, pp. 495-508  Examiner Interview Summary for US Application No. 10/344,534, dated February 5, 2008  Extended European Search Report, Application No. EP 09004189.8-1222/2070542, December 8, 2009, 6 pages  FUNARO et al., "Stimulation of T Cells via CD44 Requires Leukoyte-Function-Associated Antigen Interactions and Interleukin-2 Production, Human Immunology, Vol. 40, No. 4, August 1994, pp. 267-278  JOHNSON et al, "Expression and Function of Insulin-Like Growth Factor Receptors on Anti-CD3-Activated Human T Lymphyocytes", Journal of Immunology, Vol. 148, No. 1, January 1, 1992, pp. 63-71  KANTO et at, "Neutralization of Transforming Growth Factor & 1 Augments Hepatitis C Virus-Specific Cytotoxic T Lymphocyte Induction In Vitro", Journal of Clinical Immunology, Vol. 17, No. 6, 1997, pp.	A 44 A 4	30	"Animal Cell Culture: A Practical Approach", Edited by R. I. Freshney, IRL Press, Oxford, Washington, DC, 1986, pp. 26-41	
BPAI Decision on Appeal for Application No. 10/344,534, dated May 28, 2010  del POZO et al., "Chemokines Regulate Cellular Polarization and Adhesion Receptor Redistribution During Lymphocyte Interaction with Endothelium and Extracellular Matrix, Involvement of cAMP Signaling Pathway", The Journal of Cell Biology, Vol. 131, No. 2, October 1995, pp. 495-508  Examiner Interview Summary for US Application No. 10/344,534, dated February 5, 2008  Extended European Search Report, Application No. EP 09004189.8-1222/2070542, December 8, 2009, 6 pages  FUNARO et al., "Stimulation of T CellIs via CD44 Requires Leukoyte-Function-Associated Antigen Interactions and Interleukin-2 Production, Human Immunology, Vol. 40, No. 4, August 1994, pp. 267-278 JOHNSON et al., "Expression and Function of Insulin-Like Growth Factor Receptors on Anti-CD3-Activated Human T Lymphyocytes", Journal of Immunology, Vol. 148, No. 1, January 1, 1992, pp. 63-71  KANTO et at, "Neutralization of Transforming Growth Factor ß-1 Augments Hepatitis C Virus-Specific Cytotoxic T Lymphocyte Induction In Vitro", Journal of Clinical Immunology, Vol. 17, No. 6, 1997, pp.		31	AZUMA et al., "Functional Expression of B7/BB1 on Activated T Lymphocytes", J. Exp. Med., Vol. 177, March 1993, pp. 845-850	
del POZO et al., "Chemokines Regulate Cellular Polarization and Adhesion Receptor Redistribution During Lymphocyte Interaction with Endothelium and Extracellular Matrix, Involvement of cAMP Signaling Pathway", The Journal of Cell Biology, Vol. 131, No. 2, October 1995, pp. 495-508  Examiner Interview Summary for US Application No. 10/344,534, dated February 5, 2008  Extended European Search Report, Application No. EP 09004189.8-1222/2070542, December 8, 2009, 6 pages  FUNARO et al., "Stimulation of T Cellis via CD44 Requires Leukoyte-Function-Associated Antigen Interactions and Interleukin-2 Production, Human Immunology, Vol. 40, No. 4, August 1994, pp. 267-278 JOHNSON et al., "Expression and Function of Insulin-Like Growth Factor Receptors on Anti-CD3-Activated Human T Lymphyocytes", Journal of Immunology, Vol. 148, No. 1, January 1, 1992, pp. 63-71  KANTO et at, "Neutralization of Transforming Growth Factor ß-1 Augments Hepatitis C Virus-Specific Cytotoxic T Lymphocyte Induction In Vitro", Journal of Clinical Immunology, Vol. 17, No. 6, 1997, pp.		32	BLUE et al . "Enhancement of CD2-Mediated T Cell Activation by the Interaction of VLA-4 with Fibronectin", Cellular Immunology, Vol. 138, 1991, pp. 238-244	<u></u>
During Lymphocyte Interaction with Endothelium and Extracellular Matrix, Involvement of cAMP Signaling Pathway", The Journal of Cell Biology, Vol. 131, No. 2, October 1995, pp. 495-508  Examiner Interview Summary for US Application No. 10/344,534, dated February 5, 2008  Examiner Interview Summary for US Application No. 10/344,534, dated February 5, 2008  Extended European Search Report, Application No. EP 09004189.8-1222/2070542, December 8, 2009, 6 pages  FUNARO et al., "Stimulation of T CellIs via CD44 Requires Leukoyte-Function-Associated Antigen Interactions and Interleukin-2 Production, Human Immunology, Vol. 40, No. 4, August 1994, pp. 267-278  JOHNSON et al, "Expression and Function of Insulin-Like Growth Factor Receptors on Anti-CD3-Activated Human T Lymphyocytes", Journal of Immunology, Vol. 148, No. 1, January 1, 1992, pp. 63-71  KANTO et at, "Neutralization of Transforming Growth Factor ß-1 Augments Hepatitis C Virus-Specific Cytotoxic T Lymphocyte Induction In Vitro", Journal of Clinical Immunology, Vol. 17, No. 6, 1997, pp.	Control British Park Control British Control B	33	BPAI Decision on Appeal for Application No. 10/344,534, dated May 28, 2010	F
Extended European Search Report, Application No. EP 09004189.8-1222/2070542, December 8, 2009, 6 pages  FUNARO et al., "Stimulation of T Cellls via CD44 Requires Leukoyte-Function-Associated Antigen Interactions and Interleukin-2 Production, Human Immunology, Vol. 40, No. 4, August 1994, pp. 267-278 JOHNSON et al, "Expression and Function of Insulin-Like Growth Factor Receptors on Anti-CD3-Activated Human T Lymphyocytes", Journal of Immunology, Vol. 148, No. 1, January 1, 1992, pp. 63-71  KANTO et at, "Neutralization of Transforming Growth Factor ß-1 Augments Hepatitis C Virus-Specific Cytotoxic T Lymphocyte Induction In Vitro", Journal of Clinical Immunology, Vol. 17, No. 6, 1997, pp.		34	During Lymphocyte Interaction with Endothelium and Extracellular Matrix, Involvement of cAMP	Г
FUNARO et al., "Stimulation of T CellIs via CD44 Requires Leukoyte-Function-Associated Antigen Interactions and Interleukin-2 Production, Human Immunology, Vol. 40, No. 4, August 1994, pp. 267-278  JOHNSON et al, "Expression and Function of Insulin-Like Growth Factor Receptors on Anti-CD3-Activated Human T Lymphyocytes", Journal of Immunology, Vol. 148, No. 1, January 1, 1992, pp. 63-71  KANTO et at, "Neutralization of Transforming Growth Factor ß-1 Augments Hepatitis C Virus-Specific Cytotoxic T Lymphocyte Induction In Vitro", Journal of Clinical Immunology, Vol. 17, No. 6, 1997, pp.		35	Examiner Interview Summary for US Application No. 10/344,534, dated February 5, 2008	Γ
JOHNSON et al, "Expression and Function of Insulin-Like Growth Factor Receptors on Anti-CD3-Activated Human T Lymphyocytes", Journal of Immunology, Vol. 148, No. 1, January 1, 1992, pp. 63-71  KANTO et at, "Neutralization of Transforming Growth Factor ß-1 Augments Hepatitis C Virus-Specific Cytotoxic T Lymphocyte Induction In Vitro", Journal of Clinical Immunology, Vol. 17, No. 6, 1997, pp.		36	Extended European Search Report, Application No. EP 09004189.8-1222/2070542, December 8, 2009, 6 pages	Г
Anti-CD3-Activated Human T Lymphyocytes", Journal of Immunology, Vol. 148, No. 1, January 1, 1992, pp. 63-71  KANTO et at, "Neutralization of Transforming Growth Factor ß-1 Augments Hepatitis C Virus-Specific Cytotoxic T Lymphocyte Induction In Vitro", Journal of Clinical Immunology, Vol. 17, No. 6, 1997, pp.		37	FUNARO et al., "Stimulation of T Cellls via CD44 Requires Leukoyte-Function-Associated Antigen Interactions and Interleukin-2 Production, Human Immunology, Vol. 40, No. 4, August 1994, pp. 267-278	F
Cytotoxic T Lymphocyte Induction In Vitro", Journal of Clinical Immunology, Vol. 17, No. 6, 1997, pp.		38	Anti-CD3-Activated Human T Lymphyocytes", Journal of Immunology, Vol. 148, No. 1, January 1, 1992,	
		39	Cytotoxic T Lymphocyte Induction In Vitro", Journal of Clinical Immunology, Vol. 17, No. 6, 1997, pp.	Г

Examiner Signature	Date Considered	

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1.</sup> Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Cheif Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

₹							
Substitut	te for form 1449B/PT	.О		Complete if Known			
INE		פוח ו	CLOSURE	Application Number	10/509,055		
				Filing Date	09-24-04		
214	ATEMENT E	or A	PPLICANT	First Named Inventor	Hiroaki Sagawa		
				Group Art Unit	1644		
	(Use as many shee	ets as n	necessary)	Examiner Name	A. JUEDES		
Sheet	4	of	7	Attorney Docket Number	1422-0644PUS1		

Examiner	Cite	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	
initial *	No. 1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т 2
	40	LAMERS et al., "Protocol for Gene Transduction and Expansion of Human T Lymphocytes for Clinical Immunogene Therapy of Cancer", Cancer Gene Therapy, Vol. 9, 2002, pp. 613-623	
	41	LEHNERT et al., Eur. J. Immunol., Vol. 28, 1998, pp. 3605-3615	
	42	Ochoa et al., "Lymphokine-Activated Killer Activity in Long-Term Cultures with Anti-CD3 Plus Interleukin 2: Identification and Isolation of Effector Subsets", Cancer Research, Vol. 49, February 15, 1989, pp. 963-968	Г
	43	Partial European Search Report, Application No. 09004189.8-1222/2070542, August 3, 2009, 3 pages	
and the second s	44	TAMURA et al., "Expression and Function of c-Met, a Receptor for Hepatocyte Growth Factor, During T-Cell Development", Scandinavian Journal of Immunology, 1998, Vol. 47, pp. 296-301	
	45	US Advisory Action for Application No. 10/344,534, dated January 18, 2008	Γ
	46	US Advisory Action for Application No. 10/344,534, dated September 24, 2007	r
	47	US Advisory Action for Application No. 11/790,025, dated April 2, 2010	
	48	US Communication for Application 10/344534, dated July 23, 2009	r
	49	US Examiner's Interview Summary for Application No. 10/344,534, June 4, 2008	
	50	US final Office Action for Application No. 10/344,534, dated March 28, 2006	Г

Examiner	Date	
Signature	Considered	

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assisstance in completing the form, call 1-800-PTO-9199 and select option 2.

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1.</sup> Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Cheif Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

Substitute for form 1449B/PTO				Complete if Known		
INIE		ו חופ	CLOSURE	Application Number	10/509,055	
				Filing Date	09-24-04	
STATEMENT BY APPLICANT			PPLICANT	First Named Inventor	Hiroaki Sagawa	
				Group Art Unit	1644	
(Use as many sheets as necessary)			ecessary)	Examiner Name	A. JUEDES	
Sheet 5 of 7		Attorney Docket Number	1422-0644PUS1			

		NON PATENT LITERATURE DOCUMENTS	
Examiner initial *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
	51	US final Office Action for Application No. 10/344,534, dated May 16, 2007	Г
<u> </u>	52	US final Office Action for Application No. 10/486,512, dated April 19, 2010	
***************************************	53	US final Office Action for Application No. 10/486,512, dated February 23, 2007	
PRINCIPATI SANTALIS, UNIQUE ARCHITICA SANTALIS	54	US final Office Action for Application No. 10/486,512, dated January 5, 2009	f
	55	US final Office Action for Application No. 10/486,512, dated June 23, 2009	F
	56	US final Office Action for Application No. 10/486,512, dated May 30, 2008	
	57	US final Office Action for Application No. 10/568,745, dated July 12, 2010	
	58	US final Office Action for Application No. 11/790,025, dated December 18, 2009	
***************************************	59	US final Office Action for Application No. 11/831,423, dated March 18, 2010	
	60	US final Office Action for Application No. 11/831,423, dated November 4, 2009	Trans.
	61	US Interview Summary for Application No. 10/344,534, dated March 19, 2007	

Examiner	Date	
Signature	Considered	

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1.</sup> Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Cheif Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Substitute for form 1449B/PTO				Complete if Known		
INE		אום וי	CLOSURE	Application Number	10/509,055	
				Filing Date	09-24-04	
STATEMENT BY APPLICANT			PPLICANI	First Named Inventor	Hiroaki Sagawa	
				Group Art Unit	1644	
	(Use as many sheets as necessary)			Examiner Name	A. JUEDES	
Sheet	6	of	7	Attorney Docket Number	1422-0644PUS1	

NON PATENT LITERATURE DOCUMENTS					
Examiner initial *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>		
	62	US Interview Summary for Application No. 10/486,512, dated August 2, 2007			
and the second s	63	US Interview Summary for Application No. 11/831,423, dated June 7, 2010	r		
	64	US non-final Office Action for Application No. 10,568,745, dated November 27,2009			
98 SALI 981 - di Addrés de Provincia antiche de constant	65	US non-final Office Action for Application No. 10/344,534, dated October 11, 2005	r		
	66	US non-final Office Action for Application No. 10/344,534, dated September 25, 2006			
	67	US non-final Office Action for Application No. 10/486,512, dated April 24, 2006			
	68	US non-final Office Action for Application No. 10/486,512, dated July 25, 2006			
	69	US non-final Office Action for Application No. 10/486,512, dated October 10, 2007			
	70	US non-final Office Action for Application No. 10/486,512, dated September 30, 2009			
	71	US non-final Office Action for Application No. 10/568,745, dated July 9, 2009			
	72	US non-final Office Action for Application No. 11/790,025, dated January 5, 2009			

Examiner		Date	
		Date	
Signature		Considered	
5		00110100100	
	112-112-112-112-112-112-112-112-112-112		

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1.</sup> Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Cheif Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known Substitute for form 1449B/PTO **Application Number** 10/509,055 INFORMATION DISCLOSURE **Filing Date** 09-24-04 STATEMENT BY APPLICANT Hiroaki Sagawa First Named Inventor Group Art Unit 1644 (Use as many sheets as necessary) **Examiner Name** A. JUEDES Attorney Docket Number Sheet 7 7 of 1422-0644PUS1

		NON PATENT LITERATURE DOCUMENTS	
Examiner initial *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropri item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume- publisher, city and/or country where published.	
	73	US non-final Office Action for Application No. 11/790,025, dated May 7, 2009	Γ
	74	US non-final Office Action for Application No. 11/831,423, dated May 27, 2009	Γ
	75	US Request for Restriction for Application No. 10/344,534, dated June 20, 200	5
AMERICAN PARTY AND			Г
			Г
			[
		·	
Examin Signatu	er re	Date Considered	10/18/2010

<sup>\*</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1.</sup> Applicants unique citation designation number. (optional) 2. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Cheif Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450 Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-4450.